Global Viral Vector and Plasmid Manufacturing Market to Reach $5.86 Billion by 2030, Reports BIS Research

According to a new market intelligence report by BIS Research titled “Global Viral Vector and Plasmid Manufacturing Market – Analysis and Forecast, 2020-2030”, the global viral vector and plasmid manufacturing market was valued at $1.16 billion in 2019 and is expected to be $5.86 billion in 2030. The viral vector and plasmid manufacturing market is expected to grow at a lower double-digit compound annual growth rate in the forecast period 2020-2030. Growing prominence of vector-based gene therapy products and high funding activities in research for the development of novel therapies, coupled with increasing prevalence of diseases, such as cancer, genetic diseases, and infectious diseases, is prominently driving the growth of the global viral vector and plasmid manufacturing market.

BIS Research Report: https://bisresearch.com/industry-report/viral-vector-plasmid-manufacturing-market.html

Rising prevalence of diseases have led to an increasing demand for the development of advanced therapies and drugs to meet the needs of the growing patient population. The advent of cell and gene therapy has offered high potential to treat diseases that are otherwise uncurable by conventional treatment modalities. Both therapies encompass the use of vector, as gene delivery vehicle, for the introduction of a therapeutic gene into the target cell in order to provide a cure or remedy to disease. Extensive progress made in gene and cell therapy research since the early 1970s and 1980s has, therefore, accelerated the adoption rate of plasmids and viral vectors for their use in these modern therapies. Progress made in the field of vaccinology, involving the use of vectors, has further intensified the demand for these vectors. A large number of preclinical and clinical studies evaluating the potential of vectors in these advanced therapies have further displayed promising results. This, in turn, has attracted the attention of investors, making viral vector and plasmid manufacturing market an active area of investment as well as encouraging favorable funding activities from both private and public sectors.

Currently, the global viral vector and plasmid manufacturing market is witnessing the entry of several contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) that are striving hard to sustain the competition with the main goal to increase the production of vectors that would be both cost-effective and of superior quality. The market is currently dominated by juggernauts, such as Lonza, Thermo Fisher Scientific Inc, Merck KGaA, GE Healthcare, Sartorius AG, and other small-medium enterprises, which offer a wide range of vector manufacturing products and services to the market. The expansion of manufacturing facilities is one of the key strategies adopted by the companies in order to strengthen their business position. Besides, collaborations, partnerships, joint ventures, and mergers, and acquisitions are also some of the common business development strategy adopted by key companies.

According to Abdul Wahid, Principal Analyst at BIS Research, “The field of oncology is the major contributor of revenue in the viral vector and plasmid manufacturing market. By disease, the market is largely dominated by cancer that contributed to 56.50% of the total market share in 2019. The cancer segment was valued at $652.5 million in 2019 and is anticipated to reach $2.14 billion in 2030, registering a low double-digit CAGR during the time period between 2020 and 2030. This is mainly attributed to the progress made in vector-based CAR-T cell therapies and increasing investments in the field of oncology for the development of advanced therapies. However, among the different disease types, infectious disease is expected to account for the highest CAGR during the forecast period between 2020 and 2030.”

Research Highlights:

• The leading players of the global viral vector and plasmid manufacturing market predominantly prefer partnerships and alliances to sustain the market competition and strengthen their business position. Most of the collaborations are taking place between contract manufacturers and biopharmaceutical companies, whereby one is offering their vector manufacturing facility, while the other one is involved in the development of vector-based cell and gene therapy products.

• Between plasmids and viral vectors, the latter led the market in 2019 with almost 80% contribution to the global revenue. The availability of a large variety of viral vectors in the market and the benefits offered by them over plasmid vectors, mainly in terms of the longer size of the therapeutic gene that it can accommodate, were responsible for their market dominance.

• Among the different viral vectors, adenovirus vector dominated the market in 2019, accounting for 26.50% of the global viral vector and plasmid manufacturing market for viral vectors. This is mainly attributed to the increased adoption rate of adenovirus vectors for performing experimental studies related to the treatment of different types of cancers, such as head and neck cancer, bladder cancer, and prostate cancer.

• In terms of application areas, gene therapy was the major contributor of revenue followed by the file of vaccinology. The gene therapy segment was valued at $486.54 million in 2019 and is anticipated to reach $2.17 billion in 2030.

• Among the different regions, North America led the global viral vector and plasmid manufacturing market in 2019, with the U.S. being the major contributor of revenue. The presence of a large number of well-equipped vector manufacturing facilities with advanced infrastructure and strong investments in the biomanufacturing sector is significantly promoting the growth of the viral vector and plasmid manufacturing market in North America.

Request for Sample Report: https://bisresearch.com/requestsample?id=866&type=download

This market intelligence report provides a multidimensional view of the global viral vector and plasmid manufacturing market in terms of market size and growth potential. This research report aims at answering various aspects of the global viral vector and plasmid manufacturing market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of market expansion.
Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities such as product launches, partnerships, and product approvals, among others. The research report provides a comprehensive analysis of the product sales, and manufacturers and trend analysis by segment and by region.

This report is a meticulous compilation of research on more than 15 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of the leading companies, market participants, and vendors. The report also profiles 15 companies including several key players, namely FUJIFILM Holdings Corporation, GENERAL ELECTRIC, Lonza, Merck KGaA, MolMed S.p.A., Novasep Holding, Oxford Biomedica plc, Catalent, Inc., Thermo Fisher Scientific, Inc., GenScript, Boehringer Ingelheim, Wuxi AppTec Co., Ltd., Sartorius AG, Takara Bio Inc., and Aldevron, L.L.C.

The answers to the following key questions can be derived from this report:
• What is a vector, and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors?
• What are the major advancements in the viral vector and plasmid manufacturing sector? What are the key trends of the global viral vector and plasmid manufacturing market? How is the market evolving and what is its future scope?
• What are the major drivers, challenges, and opportunities of the global viral vector and plasmid manufacturing market?
• What are the key developmental strategies implemented by the key players of the global viral vector and plasmid manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
• What is the regulatory scenario of the global viral vector and plasmid manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral vector and plasmid manufacturing products?
• What are major milestones in patenting activity in the global viral vector and plasmid manufacturing market?
• What was the market size of the global viral vector and plasmid manufacturing market in 2019, and what is the market size anticipated to be in 2030? What is the expected growth rate of the global viral vector and plasmid manufacturing market during the period between 2020 and 2030?
• What is the global market size for manufacturing plasmids and different types of viral vectors available in the global viral vector and plasmid manufacturing market in 2019? What are the key trends of the market with respect to different vectors and which vector type is expected to dominate the market during the forecast period 2020-2030?
• What are the different disease areas where plasmids and viral vectors are employed in the global viral vector and plasmid manufacturing market? Which disease type dominated the market in 2019 and is expected to dominate in 2030?
• What are the different applications associated with viral vector and plasmid manufacturing? What was the contribution of each of the application areas in the global viral vector and plasmid manufacturing market in 2019, and what is it expected in 2030?
• Which region is expected to contribute the highest sales to the global viral vector and plasmid manufacturing market during the period between 2019 and 2030? Which region and country carry the potential for significant expansion of key companies in the viral vector and plasmid manufacturing market? What are the leading countries of different regions that contribute significantly toward the growth of the market?
• Which are the key players of the global viral vector and plasmid manufacturing market, and what are their roles in the market? What was the market share of the key players in 2019?

Related Reports:

Global Next-Generation Biomanufacturing Market : https://bisresearch.com/industry-report/next-generation-biomanufacturing-market.html

Global Cell and Gene Therapy Market: https://bisresearch.com/industry-report/cell-gene-therapy-market.html

Global Biologics Drug Discovery Market: https://bisresearch.com/industry-report/global-biologics-drug-discovery-market-2025.html

Contact:
Bhavya Banga
Email: media@bisresearch.com
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT CA 94538-1686
Visit our Blog @ http://bisresearch.com/blog/
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch

About BIS Research:

BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.
With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.
Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
What distinguishes BIS Research from the rest of the players is that we don’t simply provide data but also complement it with valuable insights and actionable inputs for the success of our clients.

This release was published on openPR.